

SAFETY DATA SHEET

SECTION 1. IDENTIFICATION

1.1 Product identifiers

Product name : **Thozalinone 50 mg Tablets**
 Product Number : THOZ-TAB
 Brand : 4AminoLabs
 CAS-No. (active) : 655-05-0 (thozalinone)
 Reference batch : See container label

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory research and analytical reference use.
 Uses advised against : Not for human or veterinary use. Not a drug, dietary supplement, food, or cosmetic. Supplied under the TSCA R&D Exemption (40 CFR Section 720.36); it is the recipient's responsibility to comply with the requirements of the R&D exemption.

1.3 Details of the supplier of the safety data sheet

Company : 4AminoLabs
 1001 S. Main Street, STE 600
 Kalispell, MT 59901
 UNITED STATES
 Telephone : +1 (256) 472-1983
 E-mail : sales@4aminolabs.com
 Website : www.4aminolabs.com

1.4 Emergency telephone number

Emergency Phone # : Poison Control Center (US): 1-800-222-1222 (24 hours/day, 7 days/week)

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Acute toxicity (Oral) : Category 4

Classification applied conservatively: no validated LD50 data are available for thozalinone, a pharmacologically active central nervous system compound (catecholamine-releasing agent). Active content approx. 19.2 % w/w (tablet weight 260 mg).

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H302 Harmful if swallowed.

Precautionary statements : Prevention:
 P264 Wash skin thoroughly after handling.
 P270 Do not eat, drink or smoke when using this product.
 Response:
 P301 + P317 IF SWALLOWED: Get medical help.
 P330 Rinse mouth.
 Storage:
 P405 Store locked up.
 Disposal:
 P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

Limited test data available for hazard assessment; handle with caution. Crushing or grinding tablets may generate airborne dust.
 Pharmacologically active substance (central nervous system stimulant class); significant exposure may cause sympathomimetic effects.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration
Thozalinone (2-(dimethylamino)-5-phenyl-4(5H)-oxazolone)	655-05-0	approx. 50 mg/tablet
Synonyms: tozalinone; Stimsen; CL-39808; NSC 170962		approx. 19.2 % w/w
Formula: C ₁₁ H ₁₂ N ₂ O ₂ Molecular weight: 204.23 g/mol		
Microcrystalline cellulose	9004-34-6	Balance
Dicalcium phosphate	7757-93-9	Balance
Magnesium stearate	557-04-0	Balance
Silicon dioxide (amorphous)	7631-86-9	Balance

Excipients are not classified as hazardous. Individual excipient percentages are withheld as trade secret.

SECTION 4. FIRST AID MEASURES

General advice	: Show this safety data sheet to the doctor in attendance.
If inhaled	: After inhalation: fresh air. Call in physician if symptoms develop.
In case of skin contact	: Take off immediately all contaminated clothing. Rinse skin with water/ shower.
In case of eye contact	: After eye contact: rinse out with plenty of water for at least 15 minutes. Remove contact lenses.
If swallowed	: After swallowing: rinse mouth, make victim drink water (two glasses at most). Do not induce vomiting. Call a physician or poison control center immediately.
Most important symptoms and effects, both acute and delayed	: Central nervous system stimulation possible with significant exposure, including restlessness, insomnia, increased heart rate, and reduced appetite. See also section 11.
Protection of first-aiders	: For personal protection see section 8.
Notes to physician	: Treat symptomatically and supportively. Thozalinone is a 2-oxazolinone analog of pemoline reported to release dopamine and, to a lesser extent, norepinephrine.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray, dry powder, foam, carbon dioxide (CO ₂).
Unsuitable extinguishing media	: For this substance/mixture no limitations of extinguishing agents are given.
Specific hazards during firefighting	: Combustible. Finely divided dust may form explosive mixtures in air.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x) Phosphorus oxides
Further information	: Suppress (knock down) gases/vapours/mists with a water spray jet. Prevent fire extinguishing water from contaminating surface water or the ground water system.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Advice for non-emergency personnel: Avoid inhalation of dusts. Avoid substance contact. Advice for emergency responders: For personal protection see section 8.
Environmental precautions	: Do not let product enter drains.
Methods and materials for containment and cleaning up	: Collect intact tablets by hand. Take up broken tablets and powder dry, avoiding generation of dusts; a HEPA vacuum may be used. Place in a closed, labeled container. Clean affected area. Dispose of properly (see section 13).

SECTION 7. HANDLING AND STORAGE

Advice on safe handling	: Handle only by qualified personnel in a laboratory setting. Crush, split, or weigh tablets only in a fume hood or ventilated enclosure. Avoid contact with skin and eyes.
Hygiene measures	: Change contaminated clothing. Wash hands after working with substance. Do not eat, drink, or smoke in work areas.
Further information on storage conditions	: Tightly closed. Dry. Protect from light and moisture. Store locked up or in an area accessible only to qualified or authorized persons.
Storage class	: 11, Combustible Solids
Recommended storage temperature	: Controlled room temperature (20 - 25 °C); 2 - 8 °C (36 - 46 °F) for long-term storage
Materials to avoid	: Strong oxidizing agents, strong acids and bases.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters				
Component	CAS-No.	Value type	Control parameter	Basis

Thozalinone	655-05-0	-	No established limit	-
Particulates not otherwise regulated (excipient dust)	-	TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable)	5 mg/m3	
Engineering measures	:	Use a fume hood or ventilated balance enclosure when tablets are crushed, split, or weighed. Provide an eyewash station.		
Personal protective equipment				
Respiratory protection	:	Required when dusts are generated. Use a NIOSH-approved N95 or P100 particulate respirator.		
Hand protection	:	Material: Nitrile rubber Glove thickness: minimum 0.11 mm Remarks: Inspect before use and dispose of after contamination.		
Eye protection	:	Safety glasses with side shields tested and approved under appropriate government standards such as NIOSH (US) or EN 166 (EU).		
Skin and body protection	:	Laboratory coat.		
Hygiene measures	:	Change contaminated clothing. Wash hands after working with substance.		

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: Solid, tablet
Color	: White
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point	: 133 - 136 °C (271 - 277 °F) (thozalinone)
Boiling point/boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Dust may be combustible
Upper/lower explosion limit	: No data available
Vapor pressure	: No data available
Relative density	: No data available
Water solubility	: thozalinone: slightly soluble in water; soluble in DMSO
Partition coefficient: n-octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	: Not applicable
Explosive properties	: No data available
Oxidizing properties	: No data available
Molecular weight	: 204.23 g/mol (thozalinone)
Particle size	: Not applicable (tablet)

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: No data available
Chemical stability	: The product is chemically stable under recommended storage conditions. The oxazolone ring may be susceptible to hydrolysis under prolonged exposure to moisture.
Possibility of hazardous reactions	: No data available
Conditions to avoid	: Heat, moisture, direct light, dust formation.
Incompatible materials	: Strong oxidizing agents, strong acids, strong bases.
Hazardous decomposition products	: In the event of fire: see section 5

SECTION 11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

No validated LD₅₀ data are available. Classified conservatively as Acute Tox. 4 (oral). Published rodent studies describe oral doses producing increased locomotor activity and alertness.

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitization

No data available

Germ cell mutagenicity

No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

Reproductive toxicity

No data available

Specific target organ toxicity - single exposure

No data available. Central nervous system stimulation possible with significant exposure.

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

Not applicable

11.2 Additional Information

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

Avoid release to the environment. This product neither contains, nor was manufactured with, a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App. A + B).

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Waste material must be disposed of in accordance with national, state, and local regulations using a licensed waste disposal contractor. Leave chemicals in original containers. No mixing with other waste. Do not dispose of in household trash or sewer.

Contaminated packaging : Handle uncleaned containers like the product itself.

SECTION 14. TRANSPORT INFORMATION

International Regulations

IATA-DGR: Not regulated as a dangerous good.

IMDG-Code: Not regulated as a dangerous good.

National Regulations

49 CFR (DOT): Not regulated as a dangerous good

Poison Inhalation Hazard : No

Special precautions for user : Not classified as dangerous in the meaning of transport regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 302 / 304 Extremely Hazardous Substances

This material does not contain any components with a section 302 EHS TPQ or section 304 EHS RQ.

SARA 311/312 Hazards : Acute toxicity (any route of exposure)
SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act

This product does not contain any hazardous air pollutants (HAP) as defined by the U.S. Clean Air Act Section 112 (40 CFR 61), nor any Class I or Class II ODS.

Clean Water Act

This product does not contain any Hazardous Substances listed under Section 311, Table 116.4A, or toxic or priority pollutants under Section 307.

Controlled substance status

Thozalinone is not listed in the schedules of the U.S. Controlled Substances Act (21 CFR 1308) as of the revision date. Its analog pemoline (CAS 2152-34-3) is a Schedule IV substance and is not a component of this product. Purchasers are responsible for verifying state and local requirements before ordering.

US State Regulations

Massachusetts Right To Know : No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know : No components are subject to the Pennsylvania Right to Know Act.
New Jersey Right To Know : No components are subject to the New Jersey Right to Know Act.
California Prop. 65 : This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.

Inventories

TSCA : Product contains substance(s) not listed on the TSCA inventory. Supplied for research and development use only under 40 CFR 720.36.

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

CAS - Chemical Abstracts Service; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; DOT - Department of Transportation; GHS - Globally Harmonized System; HEPA - High-Efficiency Particulate Air; IARC - International Agency for Research on Cancer; IATA-DGR - International Air Transport Association Dangerous Goods Regulations; IMDG - International Maritime Dangerous Goods; LD50 - Lethal Dose to 50% of a test population; NIOSH - National Institute for Occupational Safety and Health; NTP - National Toxicology Program; ODS - Ozone Depleting Substance; OSHA - Occupational Safety and Health Administration; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TSCA - Toxic Substances Control Act; TWA - Time Weighted Average.

For research use only. Not for human or veterinary use. The information is believed to be correct but is not exhaustive and shall be used solely as a guideline, based on current knowledge of the chemical substance or mixture, and is applicable to appropriate safety precautions for the product. It does not represent any guarantee of the properties of the product. 4AminoLabs shall not be held liable for any damage resulting from handling or from contact with the above product. The burden of safe use rests with the user.

Revision Date : 10/03/2026
Version : 1.0